Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Assets: 2016-2024

Historic Non-Current Assets for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $9.6 million.

  • UroGen Pharma's Non-Current Assets rose 141.02% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year increase of 141.02%. This contributed to the annual value of $9.6 million for FY2024, which is 4.94% up from last year.
  • UroGen Pharma's Non-Current Assets amounted to $9.6 million in FY2024, which was up 4.94% from $9.1 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Non-Current Assets registered a high of $9.6 million during FY2024, and its lowest value of $5.4 million during FY2021.
  • Over the past 3 years, UroGen Pharma's median Non-Current Assets value was $9.1 million (recorded in 2023), while the average stood at $8.5 million.
  • As far as peak fluctuations go, UroGen Pharma's Non-Current Assets slumped by 88.12% in 2020, and later spiked by 35.95% in 2023.
  • Over the past 5 years, UroGen Pharma's Non-Current Assets (Yearly) stood at $6.4 million in 2020, then fell by 16.13% to $5.4 million in 2021, then climbed by 25.32% to $6.7 million in 2022, then soared by 35.95% to $9.1 million in 2023, then climbed by 4.94% to $9.6 million in 2024.